Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13677MR)

This product GTTS-WQ13677MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13677MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9141MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMGN-289
GTTS-WQ9954MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KBSA301
GTTS-WQ1822MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ1959MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGS-15E
GTTS-WQ15846MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ12155MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-009
GTTS-WQ13898MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-2176
GTTS-WQ15954MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW